SEC Comment Letter 0000000000-24-013645 to PRF Technologies Ltd. (PRFX)
PRF Technologies Ltd.
Date: Dec. 11, 2024 · CIK: 0001801834 · Accession: 0000000000-24-013645
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283655
Letter
December 11, 2024 Ehud Geller, Ph.D. Interim Chief Executive Officer and Director PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 Re:PainReform Ltd. Registration Statement on Form F-3 Filed December 6, 2024 File No. 333-283655 Dear Ehud Geller Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
December 11, 2024
Ehud Geller, Ph.D.
Interim Chief Executive Officer and Director
PainReform Ltd.
65 Yigal Alon St.
Tel Aviv, Israel 6744316
Re:PainReform Ltd.
Registration Statement on Form F-3
Filed December 6, 2024
File No. 333-283655
Dear Ehud Geller Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.